source
- FDA approves Priovant's Lisraya (brepocitinib) for rare skin disease dermatomyositisThe U.S. Food and Drug Administration has cleared the first oral targeted treatment for dermatomyositis, a rare and disabling skin disorder. The medication, brepocitinib, will be sold under the br…
- AstraZeneca and Amgen report positive Phase 3 results for Tezspire in eosinophilic esophagitisAstraZeneca and Amgen announced that their joint drug Tezspire met primary and secondary endpoints in a late-stage Phase 3 trial for eosinophilic esophagitis. The antibody targets TSLP and had pre…